These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26987239)

  • 21. [Physiotherapy from the view of health insurance financing].
    Géher P
    Orv Hetil; 2013 Dec; 154(48):1917-23. PubMed ID: 24273291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Health insurance pharmaceutical expenditures in Hungary].
    Eisingerné Balassa B; Csákvári T; Ágoston I
    Orv Hetil; 2019 Feb; 160(Suppl 1):49-54. PubMed ID: 30724598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.
    Duarte DM; Beatriz da Silva Lima M; Sepodes B
    Regul Toxicol Pharmacol; 2020 Dec; 118():104810. PubMed ID: 33122047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. For the Sake of Justice: Should We Prioritize Rare Diseases?
    Juth N
    Health Care Anal; 2017 Mar; 25(1):1-20. PubMed ID: 25145639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of orphan drugs on Latvian budget.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HEALTH INSURANCE ASPECTS OF PHYSIOTHERAPEUTIC CARE OF NEUROLOGY DISORDERS IN OUTPATIENT CARE].
    Molics B; Boncz Imre ; Leidecker E; Horváth Z; Sebestyén A; Kránicz J; Komoly S; Dóczi T; Oláh A
    Ideggyogy Sz; 2015 Nov; 68(11-12):399-408. PubMed ID: 26821514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unintended effects of orphan product designation for rare neurological diseases.
    Murphy SM; Puwanant A; Griggs RC;
    Ann Neurol; 2012 Oct; 72(4):481-90. PubMed ID: 23109143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The European challenges of funding orphan medicinal products.
    Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
    Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orphan drug policies and use in pediatric nephrology.
    Karpman D; Höglund P
    Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The long-term effect of generic price competition on the Hungarian statin market.
    Répásy B; Gazsó T; Elmer D; Pónusz-Kovács D; Kajos FL; Csákvári T; Kovács B; Boncz I
    BMC Health Serv Res; 2023 May; 23(1):447. PubMed ID: 37147682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drugs for rare diseases: the blessing of being orphans.].
    Costa E; Schieppati A; Luzzatto L; Remuzzi G
    Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.